[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610378":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":16,"locations":21,"responsibleParty":39,"collaborators":7,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":7,"eligibilityCriteria":46,"healthyVolunteers":43,"sex":47,"minAge":48,"maxAge":7,"enrollmentInfo":49,"targetDuration":7,"studyType":52,"phases":7,"briefSummary":53,"conditions":54,"keywords":7,"overallStatus":24,"whyStopped":7,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},{"fullName":5,"class":6},"M.D. Anderson Cancer Center","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"Questionnaire","patient-reported outcomes questionnaire",[13],{"name":14,"affiliation":5,"role":15},"Victoria E Banuchi, MD","PRINCIPAL_INVESTIGATOR",[17],{"name":14,"role":18,"phone":19,"phoneExt":7,"email":20},"CONTACT","346-217-8668","vebanuchi@mdanderson.org",[22],{"facility":23,"status":24,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"MD Anderson Cancer Center","RECRUITING","Houston","Texas","77030","United States","US",{"type":31,"coordinates":32},"Point",[33,34],-95.36327,29.76328,{"lat":34,"lon":33},[37,38],{"name":14,"role":18,"phone":19,"phoneExt":7,"email":20},{"name":14,"role":15,"phone":7,"phoneExt":7,"email":7},{"type":40,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100610378","nanosecond-pulsed-field-ablation-in-the-management-of-benign-thyroid-nodules-100610378",false,"NCT07226804","Nanosecond Pulsed Field Ablation in the Management of Benign Thyroid Nodules","Eligibility Criteria\n\n* Scheduled to undergo ultrasound guided nsPFA as standard of care\n* Age 18 to 80 years.\n* Capable of providing independent consent.\n* Presence of biopsy-confirmed benign thyroid nodule , defined as one of the following:\n\n  * Benign FNA X 2 or\n  * Benign US guided FNA X 1 + benign thyroid nodule ultrasound appearance (TI-RADS 2) or\n  * Benign FNA X 1 and radiographic\u002Flaboratory evidence of functional nature\n* Nodule measuring \\>2cm in greatest dimension\n* Presence of compressive symptoms reasonably attributable to thyroid nodule (i.e. pressure sensation, dysphagia, dysphonia, respiratory distress)\n* No abnormal cervical lymph nodes during screening visit .\n\nExclusion Criteria\n\n* Age \\\u003C18\n* Patients considered unsuitable for nsPFA by the treating physician","ALL","18 Years",{"count":50,"type":51},30,"ESTIMATED","OBSERVATIONAL","To observe the outcomes of nsPFA therapy to treat benign thyroid nodules.",[55,56],"Thyroid Nodules","Pulsed Field Ablation","2026-05-29",{"date":59,"type":60},"2026-06-01","ACTUAL",{"date":62,"type":60},"2025-11-14",{"date":64,"type":51},"2030-08-31",{"name":5,"class":6},1]